EcoDrugPlus

5'-Nucleotidase Ecto

Ensembl ID : ENSCGOG00000016201
Gene Symbol: NT5E
3 Cross references
190 Possible Orthologues:

5'-Nucleotidase-Like

Ensembl ID : ENSCGOG00000022171
Gene Symbol: LOC115027195
3 Cross references
194 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a-Beta

Ensembl ID : ENSCGOG00000005533
Gene Symbol: LOC115016776
3 Cross references
138 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSCGOG00000022185
Gene Symbol: HTR1B
3 Cross references
183 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSCGOG00000004241
Gene Symbol: HTR1E
1 Cross references
150 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSCGOG00000017074
Gene Symbol: HTR2A
1 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a-Like

Ensembl ID : ENSCGOG00000017826
Gene Symbol: LOC115023623
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSCGOG00000020680
Gene Symbol: HTR2B
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSCGOG00000003639
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSCGOG00000003633
Gene Symbol: HTR3B
2 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSCGOG00000002495
Gene Symbol: HTR5A
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSCGOG00000020186
Gene Symbol: HTR6
3 Cross references
115 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).